Form 4: Oruka Therapeutics Executive Executes Stock Option Plan

Arjun Agarwal, Senior Vice President of Finance at Oruka Therapeutics, exercised stock options and sold shares under a pre-established Rule 10b5-1 trading plan.

Summary

• Arjun Agarwal, SVP of Finance, exercised options for 7,833 shares of Oruka Therapeutics common stock.
• The exercise involved 2,000 shares at $12.50 and 5,833 shares at $34.39.
• Following the exercise, the executive sold 10,290 shares in multiple transactions at weighted average prices ranging from $58.34 to $61.16.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on February 11, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transactions were pre-planned and represent routine executive financial management.

Positives

• The executive maintains a significant remaining beneficial ownership of 16,406 shares of common stock.
• The transactions were executed under a pre-planned Rule 10b5-1 program, indicating systematic rather than reactive selling.

Negatives

• The filing reflects a net reduction in the executive's direct shareholding position.

Risks

• Future share price volatility may impact the value of remaining unexercised options.
• Reliance on Rule 10b5-1 plans does not eliminate market risk for the reporting person.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that insider selling via Rule 10b5-1 plans is a standard practice for corporate executives to manage personal liquidity and diversify holdings without triggering concerns regarding non-public information.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for biotech executives to ensure compliance with SEC regulations while liquidating equity compensation.

Stakeholder Impact

• Minimal impact on shareholders as the sales were conducted under a pre-arranged plan.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

Oruka Therapeutics, ORKA, Insider Trading, Form 4, Stock Options, Rule 10b5-1